Welsis (WLSS) FCF Margin (2022 - 2023)
Welsis' quarterly FCF Margin came in at 423.3% in Q4 2023, down 24581.0% year-on-year from N/an in Q4 2022, and down 2297.22% quarter-over-quarter from 19.27% in Q3 2023.
Welsis has reported FCF Margin for 2 years, with the latest figure at 423.3% in Q4 2023.
- For the quarter ending Q4 2023, FCF Margin fell 24581.0% year-over-year to 423.3%; the trailing twelve-month figure through Sep 2024 stood at 1498.95% (down 142817.0% YoY), and the FY2024 full-year result was 1498.95%, down 142817.0% from the prior year.
- FCF Margin for Q4 2023 stood at 423.3%, down from 19.27% in the prior quarter.
- The five-year high for FCF Margin was 25.77% in Q2 2023, with the low at 423.3% in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 11.94% |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 3.30% |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 23.01% |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 23.62% |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 73.79% |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 22.17% |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | 17.24% |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | -8.19% |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 13.57% |
| 10 | Welsis | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -423.30% |
| Sep 30, 2023 | 19.27% |
| Jun 30, 2023 | 25.77% |
| Dec 31, 2022 | -177.49% |